Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round‐table session-Reference-Cited by-同舟云学术

Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round‐table session

Published:2020-07 Issue:S1 Volume:29 Page:67-72
ISSN:0906-6705
Container-title:Experimental Dermatology
language:en
Short-container-title:Exp Dermatol

Author:

Zouboulis Christos C.¹,Gulliver Wayne²³,Ingram John⁴,Kirby Brian⁵,Giamarellos‐Bourboulis Evangelos J.⁶,Podda Maurizio⁷,Tzellos Thrasyvoulos⁸,Jemec Gregor B. E.⁹¹⁰

Affiliation:

1. Departments of Dermatology, Venereology, Allergology and Immunology Dessau Medical Center Brandenburg Medical School Theodor Fontane Dessau Germany

2. Memorial University of Newfoundland St. John’s NL Canada

3. NewLab Clinical Research Inc St. John’s NL Canada

4. Division of Infection and Immunity Department of Dermatology and Academic Wound Healing Cardiff University Cardiff UK

5. St Vincent’s University Hospital and Charles Institute University College Dublin Dublin Ireland

6. 4th Department of Internal Medicine Medical School National and Kapodistrian University of Athens Athens Greece

7. Klinikum Darmstadt Darmstadt Germany

8. Institute of Clinical Medicine University of Tromsø Tromsø Norway

9. Department of Dermatology Zealand University Hospital Roskilde Denmark

10. Health Sciences Faculty University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Subject

Dermatology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.14123

Reference38 articles.

1. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process

2. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

3. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

4. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials;The Lancet;2024-06

2. S2k‐Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa – Kurzfassung;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-06

3. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa – Short version;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-05-21

4. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials;British Journal of Dermatology;2024-03-12

5. S2k-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (ICD-10-Code: L73.2);Aktuelle Dermatologie;2024-02